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Abstract: As macrophages exhibit a huge functional plasticity under homeostasis and pathological
conditions, they have become a therapeutic target for chronic inflammatory diseases. Hence,
the identification of macrophage subset-specific markers is a requisite for the development of
macrophage-directed therapeutic interventions. In this regard, the macrophage-specific Folate
Receptor β (FRβ, encoded by the FOLR2 gene) has been already validated as a target for molecular
delivery in cancer as well as in macrophage-targeting therapeutic strategies for chronic inflammatory
pathologies. We now show that the transcriptome of human macrophages from healthy and
inflamed tissues (tumor; rheumatoid arthritis, RA) share a significant over-representation of
the “anti-inflammatory gene set”, which defines the gene profile of M-CSF-dependent IL-10-producing
human macrophages (M-MØ). More specifically, FOLR2 expression has been found to strongly correlate
with the expression of M-MØ-specific genes in tissue-resident macrophages, tumor-associated
macrophages (TAM) and macrophages from inflamed synovium, and also correlates with the presence
of the PU.1 transcription factor. In fact, PU.1-binding elements are found upstream of the first exon of
FOLR2 and most M-MØ-specific- and TAM-specific genes. The functional relevance of PU.1 binding
was demonstrated through analysis of the proximal regulatory region of the FOLR2 gene, whose
activity was dependent on a cluster of PU.1-binding sequences. Further, siRNA-mediated knockdown
established the importance of PU.1 for FOLR2 gene expression in myeloid cells. Therefore, we provide
evidence that FRβ marks tissue-resident macrophages as well as macrophages within inflamed tissues,
and its expression is dependent on PU.1.
Keywords: macrophages; inflammation; rheumatoid arthritis; tumor-associated macrophages;
folate receptor
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1. Introduction
Macrophages are phagocytic cells present in all tissues, whose huge functional plasticity allows
them to drive promotion and resolution of inflammatory responses. Regardless of their origin,
tissue-resident macrophages perform essential functions for maintenance of homeostasis [1], and usually
exhibit more reparative and anti-inflammatory tasks than newly recruited blood-borne tissue-infiltrating
macrophages [2] during inflammatory responses in numerous tissues [3–9]. As a representative example,
tissue-resident macrophages in the lining layer of inflamed joints express higher levels of IL-10 than
infiltrating macrophages during rheumatoid arthritis [10,11]. Macrophage Colony-Stimulating Factor
(M-CSF), constitutively present in serum, promotes the differentiation and survival of tissue-resident and
monocyte-derived macrophages (M-MØ) [12–15], and drives the acquisition of their anti-inflammatory
and immunosuppressive functions (IL10high TNFlow IL23low IL6low) [16–20]. As a representative
example, M-CSF determines the development and maturation of Kupffer cells [21], which have been
implicated in both immunogenic and tolerogenic functions [22,23]. M-CSF triggers the acquisition
of a characteristic gene expression profile that includes an “anti-inflammatory gene set” [19,24–27],
whose presence characterizes human-tissue-resident macrophages [27–30] as well as tumor-associated
macrophages (TAM) in vivo [16]. In fact, targeting the M-CSF/M-CSF receptor axis has been shown to
reduce the presence of anti-inflammatory TAM in various tumors [31–33].
The “anti-inflammatory gene set” includes 170 genes whose expression is associated with the potent
production of IL-10 after M-MØ stimulation. The expression of the “anti-inflammatory gene set”
is critically dependent on the MAFB transcription factor in vitro [34,35] and might be also under
the control of MAF in vivo [36,37]. The FOLR2 gene is a member of the “anti-inflammatory gene
set” that codes for the Folate Receptor β, a GPI-linked cell surface receptor with a high affinity for
binding of folic acid (vitamin B9), whose physiologically reduced form (5-methyltetrahydrofolate) is
a co-factor in one-carbon transfer reactions required for DNA and RNA synthesis, epigenetic processes,
cellular proliferation and survival [38]. FRβ is a member of a family of reduced folate and folic acid
receptors that also includes FRα, FRδ and FRγ, which differ in their respective cellular distribution
and ligand selectivity [39]. While FRα is primarily expressed on the apical surface of epithelial cells
and various tumors of epithelial origin [39–41], FRδ marks regulatory T cells and oocytes [42], and
FRβ appears to be myeloid-restricted [43–45], although the molecular basis for its tissue-restricted
expression remains unknown.
Macrophage reprogramming has been proposed as a therapeutic strategy for chronic inflammatory
diseases [46]. Consequently, the identification of macrophage subset-specific markers is a requisite for
the development of macrophage-directed therapeutic interventions for human pathologies. Because of
its high affinity for folate binding and endocytosis, FRβ has been successfully used as a molecular
target in therapeutic strategies for drug delivery and immune recognition in cancer and inflammatory
pathologies [47,48]. In the present manuscript, we explore expression of FOLR2-encoded FRβ
by tissue-resident macrophages in non-inflamed tissues and in TAM of various origins, and its
correlation with the presence of genes commonly associated with the anti-inflammatory capacity
of macrophages. Further, we investigate the dependence of the macrophage-specific expression of
FOLR2 on the ETS-domain transcription factor PU.1, which is essential for terminal myeloid cell
differentiation [49,50] and control of expression of the M-CSF receptor [51]. Our results indicate that
FRβ is a useful marker for tissue-resident macrophages and macrophages within inflamed tissues, and
that its expression correlates with and depends on the expression of the PU.1 transcription factor.
2. Materials and Methods
2.1. Cell Culture and Flow Cytometry
The human cell lines K562, THP-1 and HeLa were obtained from the Centro de Investigaciones
Biológicas Cell line repository. The cell lines K562 and THP-1 were cultured in RPMI supplemented
with 10% fetal calf serum (FCS) at 37 ◦C in a humidified atmosphere with 5% CO2. HeLa cells
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were maintained in DMEM supplemented with 10% FCS. Monocyte-derived macrophages M-MØ
were generated in the presence of M-CSF, as previously described [34]. Phenotypic analysis was
carried out by indirect immunofluorescence using a mouse anti-human-FRβ antibody [52] and using
isotype-matched monoclonal antibody as a negative control. Folate-FITC endocytosis assays were
done as previously reported [45].
2.2. Transfections, Plasmids, and Site-Directed Mutagenesis
In reporter gene experiments, the FOLR2-based reporter gene construct pFOLR2-200Luc [19]
was transfected in HeLa cells using Superfect (Qiagen, Hilden, Germany) and in THP-1 cells through
the use of the Cell Line Nucleofector Kit V (Amaxa, Cologne, Germany). The amount of DNA in
each transfection was normalized by using the corresponding insertless expression vector (CMV-Ø)
as a carrier. Each transfection experiment was performed at least three times with different DNA
preparations. Transfection efficiencies were normalized by co-transfection with the pCMV-ßgal plasmid,
and β-galactosidase levels were determined using the Galacto-Light kit (Tropix, Bedford, MA 01730,
USA). The PU.1 expression plasmid has been previously described [53]. Site-directed mutagenesis on
the pFOLR2-200Luc promoter construct was done using the QuikChange System (Stratagene, La Jolla,
CA 92037, USA). For mutation of the PU.1-64 and PU.1-60 elements, the oligonucleotides PU.1-64mutS
(5′CCTTGAAGAGGGTGGGGTGACGATCCGATGGAAGAGAGGAAGGAGAATAG-3′) and
PU.1-64mutAS (5′-CTATTCTCCTTCCTCTCTTCCATCGGATCGTCACCCCACCCTCTTCAAGG-3′)
were used, and the resulting plasmid was termed pFOLR2-200PUmut2Luc. Generation
of the pFOLR2-200PUmut4Luc plasmid, where the PU.1-binding sequences PU.1-64,
PU.1-60, PU.1-55 and PU.1-47 are mutated, was accomplished by site-directed
mutagenesis on the pFOLR2-200PUmut3Luc plasmid, using the oligonucleotides PU.1-47S
(5′-GGTGACGATCCGATCGATGACTCGATGGAGAATAGCTAAGTAGGG-3′) and PU.1-47AS
(5′-CCCTACTTAGCTATTCTCCATCGAGTCATCGATCGGATCGTCACC-3′). DNA constructs and
mutations were confirmed by DNA sequencing. DNA sequencing was performed at the Genomics
Unit of the Hospital General Universitario Gregorio Marañón.
2.3. Melanoma Xenograft Model
Immunodeficient NOD-scid-IL2Rgnull (NSG) mice (The Jackson Laboratory, Bar Harbor, ME 04609,
USA) were maintained under specific pathogen-free conditions. Male mice (4–6 weeks of age) were
subcutaneously inoculated with 106 BLM melanoma cells. When tumors reached approximately 1 cm
in width (approximately at day 14th), mice were euthanized and tumors were resected and frozen for
histologic analyses. This procedure was approved by the IiSGM animal care/use and Comunidad de
Madrid committees (PROEX-084/18).
2.4. Confocal Microscopy and Immunohistochemistry
Normal skin samples were obtained from abdominoplasty. Normal colon and muscle samples
were localized adjacent to tumor and obtained from colon adenocarcinoma and melanoma patients.
Informed consent was obtained, and all the procedures were performed following Medical Ethics
Committee (Hospital General Universitario Gregorio Marañón) guidance. Thick sections (4 µm in
depth) of cryopreserved tissue were first blocked for 10 min with 1% human immunoglobulins and
then incubated for 1 h with either a mouse monoclonal antibody against human FRβ [52], a rat
monoclonal antibody against murine FRβ [48], an anti-CD163 monoclonal antibody (clone Ber-Mac3,
MBL International Corp., Woburn, MA 01801, USA), an anti-Von Willebrand factor (rabbit polyclonal,
Dako, Santa Clara, CA 95051, USA), an anti-F4/80 (clone BM8, labeled with Alexa Fluor 647, Biolegend,
San Diego, CA 92121, USA), or isotype-matched control antibodies. All primary antibodies were
used at 1–5 µg/mL, followed by incubation with Cy3-labeled anti-mouse and Cy5-labeled anti-rabbit
secondary antibodies. Tissues were imaged with the 20X PL-APO NA 0.7 immersion objective of
a confocal scanning inverted AOBS/SP2-microscope (Leica Microsystems, Wetzlar, 35578 Germany).
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Image processing was assessed with the Leica Confocal Software LCS-15.37. Tissue microarrays
(SuperBio Chips AC1 Human, Clinisciences, 92000 Nanterre, France) were processed according to
manufacturer´s recommendations and stained with a mouse monoclonal antibody against CD68
(PG-M1; Dako, Santa Clara, CA 95051, USA) and a rabbit polyclonal antibody against FRβ [54].
2.5. Quantitative Real Time RT-PCR
Oligonucleotides for selected genes were designed according to the Roche software for quantitative
real-time PCR, and RNA was amplified using the Universal Human Probe Roche Library (Roche
Diagnostics, Indianapolis, IN 46256, USA). Assays were made in triplicate and results normalized
according to the expression levels of GAPDH. In all cases, the results were expressed using the ∆∆CT
method for quantitation.
2.6. siRNA-Mediated Knockdown
THP-1 cells (2 × 106 cells) were nucleofected with 3 µg of siRNA for PU.1 (sc-36330 PU.1 siRNA
gene silencer; Santa Cruz Biotechnology, Dallas, Texas 75220 USA) or a negative control siRNA
(sc-37007 Control siRNA-A; Santa Cruz Biotechnology, Dallas, Texas 75220 USA) using the Cell Line
Nucleofector Kit V (Amaxa, Cologne, Germany). After nucleofection, cells were kept in culture for
24 h, and one-fifth of the cells were lysed and subjected to Western Blot for PU.1 detection. Total RNA
was isolated from the remaining nucleofected cells and subjected to real time-PCR.
2.7. Bioinformatic Analysis
The genes selectively expressed by monocytes and macrophages from human gut were obtained
from [55] and used to identify those genes contained within the “Pro-inflammatory gene set” and
“Anti-inflammatory gene set” previously defined [19,29]. A list of genes specifically expressed by
macrophages within melanoma [56] and head and neck squamous carcinoma [57] was derived using
Cibersortx [58], and their expression in breast carcinoma determined using the METABRIC (Molecular
Taxonomy of Breast Cancer International Consortium) study cohort [59,60] on the cBioPortal for Cancer
Genomics [61] and using the TIMER resource [62–64] on data generated by The Cancer Genome
Atlas Program Research Network [65]. Identification of genes co-expressed with FOLR2 in various
tissues was done using Genevestigator® [66]. Gene ontology analysis of the defined gene sets was
performed using the online tool ENRICHR [67,68]. Chip-seq data were derived from the Cistrome
data browser [69] and processed using the WashU Epigenome Browser [70].
2.8. Statistical Analysis
Statistical analysis was performed using a paired Student´s t-test and a p value < 0.05 was
considered significant.
3. Results
3.1. Folate Receptor Beta (FRβ) is Co-Expressed with other Genes of the “Anti-Inflammatory Gene Set” and
Marks Human Tissue-Resident Macrophages
We have previously reported the existence of transcriptional overlaps between the variety of
macrophage subsets that make up Tumor-Associated Macrophages (TAM) and M-CSF dependent
macrophages, as both are enriched in the expression of the 170-gene “anti-inflammatory gene set” [19,29],
which includes the FRβ-encoding FOLR2 gene [45]. Assessment of the genes significantly co-expressed
with FOLR2 in 431 anatomical locations identified various genes of the “anti-inflammatory gene set”,
including CD209, C1QC, CD163, LILRB5, F13A1, STAB1, RNASE1 and IGF1, with Pearson´s correlation
coefficients ranging from 0.77 to 0.65 (Figure 1A). In line with these findings, analysis of monocytes
or macrophages from human colon, whose transcriptomes have been extensively analyzed [55], also
revealed an enrichment of the “anti-inflammatory gene set” (Figure 1B), also including the expression of
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CD209, C1QC, CD163, LILRB5, F13A1 and IGF1 from the “anti-inflammatory gene set” (Figure 1C). Given
these results, FOLR2-encoded FRβ expression was evaluated in colon and other tissue macrophages
under homeostatic conditions. In agreement with the transcriptional data, and using tissue arrays, an
FRβ-specific antiserum [54] stained numerous cells in the lamina propria of the colon, where CD68+
macrophages were also detected (Figure 1D). Besides, FRβ+ cells were found in the paracortical area of
the tonsil and, to a lesser extent, in skeletal muscle (Figure 1D). Further, multicolor immunofluorescence
revealed that FRβ is co-expressed with the hemoglobin/haptoglobin scavenger receptor CD163 in
lamina propria macrophages, as well as in tonsil and in skeletal muscle, thus indicating that FRβ marks
tissue-resident macrophages (Figure 1E). In addition, FRβ was co-expressed with CD163 in the dermis
(Figure 1F), where most FRβ+/CD163+ macrophages exhibited a perivascular distribution (Figure 1F),
as well as in placenta [71] (Figure 1G). Therefore, FRβ is broadly expressed in vivo by tissue-resident
macrophages, where its expression positively correlates with the macrophage marker CD163 and other
genes of the “anti-inflammatory gene set”.
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Figure 1. Expression of FOLR2 and FRβ in human tissue-resident macrophages. (A) Identification
of genes of the “anti-inflammatory gene set” whose expression most significantly correlate with
FOLR2 expression, using Genevestigator® [66]. Pearson´s correlation coefficients are indicated in each
case. (B) Overlapping of M-MØ-specific and GM-MØ-specific genes within the lists of monocyte-
or macrophage-restricted genes in human colon samples [55]. (C) Identification of M-MØ-specific
genes specific within the lists of monocyte- and macrophage-restricted genes in human colon samples.
(D) FRβ expression in distinct normal tissues. Light microscopy images of the macrophage marker
CD68 and FRβ staining in colon, tonsil and skeletal muscle (magnification, ×20). The right panel
indicates a higher magnification (magnification ×40) for FRβ staining. Left, staining yielded by normal
rabbit serum, used as a control (pre-immune); (E) Co-expression of FRβ and CD163 in colon, tonsil
and skeletal muscle. Confocal images of human colon, tonsil and skeletal muscle tissue sections,
as determined by double immunofluorescence analysis of CD163 (green) and FRβ (red) expression.
Yellow color indicates the FRβ/CD163 merged colocalizing areas. Right panels show a magnification of
a FRβ/CD163 colocalizing area (marked in a box in left panels); (F–G) Co-expression of FRβ and CD163
in human dermis (F) and placenta (G). Confocal images of human tissue sections, as determined by
triple immunofluorescence analysis of Von Willebrand factor (white), CD163 (green) and FRβ (red)
expression. Yellow color indicates the FRβ/CD163 merged co-localizing areas. The area marked by
boxes is shown at a higher magnification in the right panel. Nuclei are counterstained with DAPI. Scale
bars: 50 µm.
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3.2. FOLR2/FRβ Expression Marks Human Tumor-Associated Macrophages and Correlates with the Expression
of CD163 and Regulators of Macrophage Differentiation
To determine whether the macrophage-restricted expression of FRβ also applies to pathological
settings, we next assessed FOLR2 expression in TAM from various tumor types. To this end, we initially
searched for macrophage-specific gene expression in melanoma [57] and head and neck squamous cell
carcinoma (HNSC) [58] (Figure 2A) and identified a set of 21 M-MØ-specific genes whose expression is
also restricted to melanoma and HNSC TAM (Figure 2B). Interestingly, FOLR2, CD163, LILRB5, CD209
and C1QC were identified as genes of the “anti-inflammatory gene set”, whose expression is also seen in
tissue-resident macrophages and tumor-associated macrophages (Figure 2B). Analysis of breast cancer
transcriptomes (METABRIC cohort) also evidenced a very good correlation between the expression of
FOLR2 and those of genes of the “anti-inflammatory gene set”, which reached statistical significance in
most cases (Figure 2C), and was highly significant for CD163 (Pearson: 0.72; p = 1.71 × 10−308) and even
CD68 (Pearson: 0.59; p = 1.25 × 10−176), another widely used marker for macrophage identification
(Figure 2C). Further, a significant correlation was found between the expression of FOLR2 and CD163
using the TCGA cohorts for breast carcinoma, melanoma and HNSC (Figure 2D and not shown),
whereas no correlation was seen between FOLR2 and the epithelial-specific EPCAM gene in any of
the analyzed tumors (data not shown). In fact, and at the protein level, FRβ expression was observed in
CD163+ cells in melanoma (Figure 2E) and in areas enriched in CD68+ cells in colon adenocarcinoma
(Figure 2F). Interestingly, and since FRβ+ macrophages are prominent in the tumor-invasive front of
pancreatic cancer and associate with poor prognosis [72], it is worth noting that FRβ+ macrophages
were mostly detected in the peritumoral area both in human melanoma and in a melanoma xenograft
mouse model (Figure 2E). Altogether, this set of results indicates that FOLR2 expression correlates
with the expression of CD163 and other macrophage-specific genes in TAM, and that FRβ expression
in TAM overlaps with the expression of the commonly used macrophage markers CD163 and CD68.
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Figure 2. Expression of FOLR2 and FRβ in human tumor-associated macrophages. (A) Overlapping of
M-MØ-specific and GM-MØ-specific genes within the lists of macrophage-specific genes in human
melanoma [57] or head and neck squamous carcinoma (HNSC) samples [58]. (B) Identification of
M-MØ-specific genes specific within the lists of macrophage-specific genes in human melanoma [57]
and head and neck squamous carcinoma samples [58]. (C) Correlation of the expression of the FOLR2
gene and the expression of the 21-gene dataset shown in B. The correlation with the expression of MAF,
MAFB and SPI1 is also shown. The shaded area indicates the significant positive correlations. (D)
Correlation of the expression of the FOLR2 gene with the expression of CD163 in breast carcinoma and
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HNSC (TCGA Cohort). (E) Co-expression of FRβ and CD163 in human melanoma (upper
panels) and a human melanoma xenograft (lower panels) using confocal microscopy after double
immunofluorescence analysis of CD163 (red) and FRβ (green) expression. Yellow color indicates
the FRβ/CD163 merged colocalizing areas. Right panels show a magnification of the FRβ/CD163
colocalizing area (marked in a box in left panels). (F) FRβ and CD68 expression in a sample of human
colon adenocarcinoma. Light microscopy images of the macrophage marker CD68 and FRβ staining
(magnification, ×20). (G) Enrichr analysis [67,68] of the genes indicated in panel B. (H) Correlation of
the expression of the FOLR2 and SPI1 genes in colon adenocarcinoma and HNSC (TCGA Cohort). (I)
Correlation of the expression of the FOLR2 gene with MAF and SPI1 expression in breast carcinoma
(METABRIC Cohort). (J) Partial correlation of FOLR2 expression with the expression of MAF or SPI1 in
the indicated tumors.
To identify potential regulators of FOLR2 gene expression, gene ontology analysis was done using
Enrichr [64], and results revealed a positive enrichment of genes regulated by MAF, SPI1 (PU.1) and
NR1H3 (LXRα) in the TAM-specific genes of the “anti-inflammatory gene set” (Figure 2G). Indeed,
FOLR2 expression was found to correlate with the expression of genes coding for transcription factors
that determine macrophage differentiation and specification (SPI1 and MAF) in breast carcinoma
(METABRIC cohort, Figure 2H), thus suggesting their involvement in expression of the FRβ-encoding
FOLR2 gene. Further analysis of a large variety of tumor types using TIMER2.0 revealed that the positive
correlation between FOLR2 and SPI1 expression was highest in colon adenocarcinoma, HNSC and
sarcoma (Figure 2I), and that the FOLR2–SPI1 correlation was more significant than the FOLR2–MAF
correlation in almost every tumor type (Figure 2J). Conversely, no significant correlation was found
between FOLR2 or SPI1 expression and the epithelial-specific EPCAM gene expression (data not
shown). Altogether, these results established a link between the FOLR2 gene and the expression of
the PU.1-encoding SPI1 gene in tumor-associated macrophages.
3.3. FOLR2/FRβ Expression also Marks Human Synovial Macrophages
Next, we address the macrophage-restricted expression of FOLR2 in a pathology where
macrophages preferentially exhibit a pro-inflammatory polarization, rheumatoid arthritis (RA). Initial
assessment of FOLR2 expression in RA indicated an extremely close correlation with the expression of
the “anti-inflammatory gene set” (Figure 3A). In fact, 13 genes of the “anti-inflammatory gene set”
were found within the 50 genes more closely correlating with FOLR2 expression in RA (Figure 3A).
Single-cell RNA sequencing (scRNA-seq) on samples from patients with rheumatoid arthritis (RA)
or osteoarthritis (OA) has identified 18 unique cell populations in synovial tissue, including four
transcriptionally different monocyte subsets [73]: IL1B+ pro-inflammatory monocytes, IFN-activated
SPP1+ monocytes, NUPR1+ monocytes and C1QA+ monocytes (Figure 3B), with the latter two subsets
under-represented in RA and thought to exert homeostatic functions [73]. Analysis of the four subsets
revealed the presence of genes of the “anti-inflammatory gene set” in IL1B+, NUPR1+ and C1QA+
monocytes, and that the expression of FOLR2 is a specific marker for the NUPR1+ monocyte subset
(Figure 3B) [73]. Indeed, although the expression of FOLR2 diminishes in macrophages from synovial
membranes [74] (Figure 3C) and from synovial fluid [75] (Figure 3D) in RA, FRβ is still detectable in
the lining layer of the synovial membrane of RA patients (Figure 3E).
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3.4. Expression of FRβ in Myeloid Cells is Dependent on the PU.1 Transcription Factor
To obtain support for the potential involvement of PU.1 in FOLR2 gene expression, we
revised the available ChIP-Seq information on the genes of the “anti-inflammatory gene set”,
which had been found to be significantly expressed in tissue-resident macrophages (Figure 1) and
TAM (Figure 2), and identified vali ated PU.1-binding sites im ediately upstream of the first
exon of most ge es (Figure 4A and not shown) [76], including FOLR2 as ell as PU.1-binding
sites within most genes of th “anti-inflammatory gene set” (Figure 4B) [77]. The presence of
3–4 major peaks in ChIP-seq data for PU.1 binding within the FOLR2 gene [74,76,77], with one
of them localized within exon 1, close to a potential FOS-binding sit [78] (Figure 4C,D) and
overlappi g a sequence c ntaining four evolutionary conserved potential Ets-binding sequences
(5′-GGAAGGGAAGGAAGAGAGGAA-3′) [79,80] (Figure 4D,E), l d us to address the control of
FOLR2 expre sion by PU.1. To analyz the functional significance of this cluster of PU.1-binding
elements, we initially evaluated its contribution to the transcriptional activity of the FOLR2 pr ximal
promoter. In HeLa cells evoid of PU.1 [81,82], transfected with the pFOLR2-200Luc co struct, which
contains the fragment -214 to -34 and includes the PU.1-binding elements, overexpression of PU.1
resulted in 10-fold enhance ent of the activity of the promoter (Figure 4F). Further, mutation of the two
distal Ets elements (pFOLR2-200PUmut2pXP2, Figure 4F) reduced PU.1-dependent transactivation
to 50% (p = 0.008), while mutation of the four Ets-sequences (pFOLR2-200PUmut4pXP2, Figure 4F)
reduced PU.1 transactivation by 86% (p = 0.009), thus implying that PU.1 exerts a positive regulatory
action on the FOLR2 proximal regulatory region through interaction with a cluster of Ets-cognate
sequences within exon 1 of the FOLR2 gene.
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the first exon of the FOLR2 gene, with indication f predicted transcription factor binding sites [70]. (D)
Schematic representation of the ChIP-Seq data on the FOLR2 gene from the indicated experiments. (E)
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(lowercase), with indication of the PU.1-binding elements. (F) HeLa cells were transfected with
the indicated FOLR2 promoter-based reporter plasmids in the presence of an empty vector or expression
vector for PU.1. For each individual reporter construct, fold induction represents the luciferase activity
yielded by PU.1 expression vector relative to the activity produced by an identical amount of empty
CMV-0 plasmid. Luciferase activity was determined after 24 h. Data represent the mean ± standard
deviation of five independent experiments using two different DNA preparations. The nucleotide
sequence of the PU.1-binding elements in the WT and mutant constructs is indicated at the top.
Having demonstrated a direct effect of PU.1 on the FOLR2 proximal regulatory region, we then
assayed the role of PU.1 on the activity of the FOLR2 promoter in the FRβ-expressing human THP-1
myeloid cell line, where the receptor is expressed in a functional state (Figure 5A,B). As shown
in Figure 5C, the pFOLR2-200PUmut4pXP2 construct exhibited significantly lower activity than
the wild-type pFOLR2-200pXP2 construct (p = 0.008) in THP-1 cells, thus indicating that the activity of
the FOLR2 gene regulatory region in myeloid cells is partly dependent on the integrity of the cluster of
PU-1-binding elements located within exon 1. To definitively prove the direct involvement of PU.1 on
FRβ expression, FOLR2 mRNA expression level was assessed after knocking down PU.1 expression
in FRβ+ THP-1 cells. Nucleofection of a PU.1-specific siRNA in THP-1 cells reduced the expression
of PU.1 by more than 50% (Figure 5D). More importantly, siRNA-mediated knockdown of PU.1 led
to a significant down-modulation of FOLR2 mRNA levels (p = 0.02 for experiment #1 and p = 0.009
for experiment #2) without affecting the expression of the functionally related PCFT gene (Figure 5E).
Therefore, PU.1 regulates FOLR2 gene expression in THP-1 cells, further confirming PU.1 dependence
on the myeloid-restricted expression of the FOLR2 gene.
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Figure 5. PU.1 enhances FOLR2 gene pro oter activity and increases F LR2 gene expression. (A)
Upper histograms, FRβ expression (empty histograms) in onocytes, K-562, THP-1 and - Ø
macrophages, as determined by flow cytometry. Lower histograms, internalization of Folate-FITC
by monocytes, THP-1, K-562 and -MØ macrophages, in the absence (black line) or the presence
(dotted line) of a 100-molar excess of folic acid. Filled histograms indicate cell autofluorescence. In
each case, the percentage of marker-positive cells and the mean fluorescence intensity (in parenthesis)
are indicated. The experiment was performed five times, and one of the experiments is shown. (B)
Detection of FOLR2 and GAPDH mRNA by RT-PCR on RNA from CD14+ peripheral blood monocytes,
K-562, THP-1 and M-MØ macrophages. Molecular size markers were loaded in lane 5. (C) THP-1 cells
were nucleofected with the indicated reporter plasmids and luciferase activity was determined after
24h. Promoter activity is expressed relative to the activity produced by the wild-type pFOLR2-200pXP2,
arbitrarily set to 1, after normalization for transfection efficiency (n = 6). (D,E) siRNA-mediated
knockdown of PU.1. THP-1 cells were nucleofected with either siRNA for PU.1 (siRNA PU.1) or
a control siRNA (siRNA CNT). After 24 h, one third of the cells were lysed and subjected to western blot
for PU.1 expression (D), and total RNA was isolated and FOLR2 and PCFT mRNA were determined by
quantitative RT-PCR (E). Results are expressed as relative mRNA levels (relative to GAPDH mRNA
levels and the corresponding mRNA level in control #1 siRNA-nucleofected cells). The experiment was
performed in duplicate, and both experiments are shown.
4. Discussion
In the present manuscript, we show that the FOLR2 gene is expressed by human CD163+
tissue-resident and tumor-associated macrophages (TAM) from various sources, and that its restricted
cellular distribution is shared by a limited number of genes, including the commonly used
macrophage-specific marker CD163. CD163 is a bona fide macrophage-specific marker [78] that,
however, is expressed at higher levels in macrophages polarized toward the anti-inflammatory and
reparative side [18,19], a property also shared by FRβ [45]. Indeed, FOLR2 expression parallels that
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of CD163 in tissue-resident macrophages, TAM from various tumor types and inflamed synovium.
Therefore, FRβ can be considered a macrophage-specific marker, in line with previous reports on its
expression in distinct macrophage subsets in human and mouse tissues [44,45,48,72,83,84]. Further
stressing its cell-restricted expression, the expression of CD163 and FOLR2 in TAM significantly
correlates with the presence of the PU.1 transcription factor. Thus, we have found that the PU.1
transcription factor, which is preferentially expressed in myeloid cells, enhances the transcriptional
activity of the proximal regulatory region of the FOLR2 gene and directly influences FOLR2 gene
expression. The demonstration of the PU.1-dependent expression of FOLR2 is the first evidence of
a transcription factor directly controlling FOLR2 expression and suggests that PU.1 contributes to
the myeloid-specific expression of FRβ.
Macrophage reprogramming now appears a feasible therapeutic strategy for chronic inflammatory
diseases [46]. Accordingly, the identification of macrophage subset-specific markers is a requisite
for the development of macrophage-directed therapeutic interventions for human pathologies.
The identification of FRβ as a macrophage-specific marker in homeostatic and pathological states
has relevant translational implications, because FRβ has already been used as a target for imaging
and delivery of therapeutic agents in inflammation-related diseases like rheumatoid arthritis [83–86].
Therefore, it is tempting to hypothesize that FRβ might also be a useful tool for delivery of agents with
ability to shift the macrophage polarization state. Such an approach would benefit from the constitutive
FRβ recycling ability [87–89] as well as by its huge capacity to transfer ligands towards the macrophage
endocytic machinery [89,90]. This strategy would be particularly well suited in the case of tumors,
as FRβ is highly expressed in TAM (this report and [45]). TAM promotes malignancy by stimulating
angiogenesis, tumor-cell migration and invasion, and TAM accrual correlates with a worse prognosis in
numerous tumors (85). Thus, FRβ constitutes an ideal target for delivery of macrophage-repolarizing
agents into TAM, and, in line with the results here presented, the characterization of the factors
that regulate FRβ expression constitutes relevant information for the development of FRβ-based
macrophage targeting strategies.
Besides the involvement of PU.1 in the myeloid expression of FRβ, bioinformatics analysis also
indicates that FOLR2 gene expression closely correlates with the expression of the MAF transcription
factor in TAM from various sources. In fact, FOLR2 exhibits the highest level of correlation with
MAF expression in breast carcinoma, a finding that agrees with the considerable decrease in FOLR2
expression that is seen upon MAF knockdown in human macrophages [74]. However, ChIP-Seq has
not provided evidence for any interaction of MAF with the FOLR2 gene. Considering the ability of
MAF to heterodimerize with members of the JUN/FOS family of transcription factors [91], and given
the existence of FOS-binding sites in exon 1 [78] and additional AP-1-binding elements nearby [79], it
is conceivable that MAF might indirectly affect FOLR2 expression by altering the levels of available
JUN/FOS family proteins.
The comparison of tissue-resident macrophage-specific genes and TAM-specific genes has resulted
in the identification of a group of six genes (MS4A6A, LILRB5, CD209, CD163, FOLR2, C1QC) which
are also preferentially/exclusively expressed by macrophages with an anti-inflammatory/reparative
polarization (included within the “anti-inflammatory” gene set). The proteins encoded by these
six genes participate in either pathogen recognition (CD209, CD163, C1QC) or in modulation of
inflammatory responses (MS4A6A, LILRB5). By contrast, and apart from its folate-binding ability, FRβ
does not appear to fit within any of these two classes, although it modulates macrophage adhesion
to collagen through association to the CD11b/CD18 integrin [92]. As a glycosyl phosphatidylinositol
(GPI)-anchored protein, FRβ’s potential to exert immunoregulatory actions would be indirect. By
contrast, the cellular distribution, structure and recycling behavior of FRβ [85] somewhat resembles
that of CD14, a crucial regulator of TLR4 ligand binding, endocytosis and TLR4-initiated signaling
from endosomes [93,94]. We speculate that FRβ might exhibit a function similar to CD14, which
acts both as a pattern-recognition receptor that binds directly to LPS and a co-receptor for several
TLRs [95]. FRβ has a very high affinity for folic acid and folates (Kd ~ 0.1–1nM), but mammals
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do not synthesize folate and are dependent on other sources. Diet or dietary supplements are not
the only sources of folate, as several bacteria in the gastrointestinal tract can synthesize B vitamins,
including folates (e.g., Lactococcus lactis, Bifidobacterium adolescentis) [96,97]. The macrophage-specific
expression of FRβ described in this report, and the fact that folic acid is produced by numerous bacterial
species [96,97], have led us to hypothesize that FRβ acts as a receptor or co-receptor for recognition of
bacterial microbiota. If so, gut macrophages could detect high concentrations of folate through FRβ as
a mechanism to control bacterial overgrowth through signaling or by phagocytosis, which would allow
the microbiota homeostasis to be restored/maintained by a folate-dependent quorum sensing-like
mechanism. Whether this mechanism contributes to the interplay between TAM and human microbiota
in cancer [98] deserves further investigation. In any event, the hypothesis that FRβ is a sensor for
adjusting macrophage effector functions to extracellular folic acid levels is fully compatible with
the findings reported in the present manuscript, namely, that FRβ marks tissue-resident macrophages
and macrophages within inflamed tissues, and that its expression correlates and is dependent on
the expression of the PU.1 transcription factor.
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